This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langenhoff, B.S. Articles by Ruers, T.J.M. Search for Related Content PubMed PubMed Citation Articles by Langenhoff, B.S. Articles by Ruers, T.J.M. Social Bookmarking                            What's this?

Efficacy of Fluorine-18-Deoxyglucose Positron Emission Tomography in Detecting Tumor Recurrence After Local Ablative Therapy for Liver Metastases: A Prospective Study

From the Departments of Surgery, Nuclear Medicine, and Radiology, University Medical Center Nijmegen, Nijmegen, the Netherlands.

Address reprint requests to T.J.M. Ruers, MD, Department of Surgery, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands; email: T.Ruers{at}heel.azn.nl

PURPOSE: The aims of this prospective study were to investigate the potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in determining the efficacy of the local tumor ablative process and to determine the added value of FDG-PET in the detection of tumor recurrence during follow-up.

PATIENTS AND METHODS: Twenty-three patients with unresectable colorectal liver metastases were followed up after local ablative therapy consisting of a standard protocol including FDG-PET scanning, computed tomography (CT) scanning, and carcinoembryonic antigen measurements. The mean follow-up period was 16 months (range, 10 to 21 months).

RESULTS: Ninety-six lesions was treated, 56 by local ablative treatment. Within 3 weeks after local ablative treatment, 51 lesions became photopenic on FDG-PET, while five lesions (in five patients) showed persistent activity on FDG-PET. In four of five FDG-PET–positive lesions, a local recurrence developed during follow-up; one FDG-PET–positive lesion turned out to be an abscess. None of the FDG-PET–negative lesions developed a local recurrence during a mean follow-up period of 16 months. During follow-up, 11 patients showed recurrence in the liver outside of the treated area. In all cases, previously negative FDG-PET scans became positive. Extrahepatic recurrence was encountered in nine patients during follow-up; FDG-PET showed all nine cases of tumor recurrence. There was one false-positive FDG-PET caused by an intra-abdominal abscess. In all patients, the time point of detection of recurrence by FDG-PET was considerably earlier than the detection by CT.

CONCLUSION: FDG-PET seems to have a significant impact in measuring treatment efficacy directly after local ablative therapy. Furthermore, FDG-PET has an added value in patient follow-up because it reveals recurrences earlier than conventional diagnostic modalities.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. J.M. Ruers, B. Wiering, J. R.M. van der Sijp, R. M. Roumen, K. P. de Jong, E. F.I. Comans, J. Pruim, H. M. Dekker, P. F.M. Krabbe, and W. J.G. Oyen Improved Selection of Patients for Hepatic Surgery of Colorectal Liver Metastases with 18F-FDG PET: A Randomized Study J. Nucl. Med., July 1, 2009; 50(7): 1036 - 1041. [Abstract] [Full Text] [PDF]

				L.-F. de Geus-Oei, D. Vriens, H. W.M. van Laarhoven, W. T.A. van der Graaf, and W. J.G. Oyen Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review J. Nucl. Med., May 1, 2009; 50(Suppl_1): 43S - 54S. [Abstract] [Full Text] [PDF]

				S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF]

				Y-x He and Q-y Guo Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms Postgrad. Med. J., May 1, 2008; 84(991): 246 - 251. [Abstract] [Full Text] [PDF]

				M.-h. Park, H. Rhim, Y.-s. Kim, D. Choi, H. K. Lim, and W. J. Lee Spectrum of CT Findings after Radiofrequency Ablation of Hepatic Tumors RadioGraphics, March 1, 2008; 28(2): 379 - 390. [Abstract] [Full Text] [PDF]

				L.F. de Geus-Oei, H. W. M. van Laarhoven, E. P. Visser, R. Hermsen, B. A. van Hoorn, Y. J. L. Kamm, P. F. M. Krabbe, F. H. M. Corstens, C. J. A. Punt, and W. J. G. Oyen Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer Ann. Onc., February 1, 2008; 19(2): 348 - 352. [Abstract] [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				A. H. Khandani, B. F. Calvo, B. H. O'Neil, J. Jorgenson, and M. A. Mauro A Pilot Study of Early 18F-FDG PET to Evaluate the Effectiveness of Radiofrequency Ablation of Liver Metastases Am. J. Roentgenol., November 1, 2007; 189(5): 1199 - 1202. [Abstract] [Full Text] [PDF]

				R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]

				F. M. Vogt, G. Antoch, P. Veit, L. S. Freudenberg, N. Blechschmid, O. Diersch, A. Bockisch, J. Barkhausen, and H. Kuehl Morphologic and Functional Changes in Nontumorous Liver Tissue After Radiofrequency Ablation in an In Vivo Model: Comparison of 18F-FDG PET/CT, MRI, Ultrasound, and CT J. Nucl. Med., November 1, 2007; 48(11): 1836 - 1844. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				G. Antoch, F. M. Vogt, P. Veit, L. S. Freudenberg, N. Blechschmid, O. Dirsch, A. Bockisch, M. Forsting, J. F. Debatin, and H. Kuehl Assessment of Liver Tissue After Radiofrequency Ablation: Findings with Different Imaging Procedures J. Nucl. Med., March 1, 2005; 46(3): 520 - 525. [Abstract] [Full Text] [PDF]

				G. Antoch, L. S. Freudenberg, T. Beyer, A. Bockisch, and J. F. Debatin To Enhance or Not to Enhance? 18F-FDG and CT Contrast Agents in Dual-Modality 18F-FDG PET/CT J. Nucl. Med., January 1, 2004; 45(90010): 56S - 65. [Abstract] [Full Text] [PDF]